Teysuno (gimeracil/oteracil/tegafur)

P2, N=400, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P2, N=20, Recruiting, Jiangsu Province Hospital; Jiangsu Province Hospital

P3, N=738, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2024 --> Sep 2025

In the first-line treatment of HER2-positive advanced gastric cancer, inetetamab and trastuzumab showed comparable efficacy. The inetetamab group showed superior PFS, and both groups had good safety.

P2/3, N=206, Not yet recruiting, Sun Yat-sen University

P2, N=30, Recruiting, Anhui Provincial Hospital

P2, N=56, Recruiting, Sun Yat-sen University

This work supports the role of toxic 5-FU metabolites generated by dihydropyrimidine dehydrogenase in the occurrence of ischemic cardiopathy among patients with gastric cancer using capecitabine.

The Dokkyo study confirmed the results observed in the Ehime study. Consequently, an increased postoperative CAR value appeared as a universal applicable marker for the risk factor of AE-related S-1 non-completion after curative surgery for patients with PC.

After three cycles of S-1, oxaliplatin, and trastuzumab, the primary tumor and metastases shrank markedly...He has been recurrence-free for seven months postoperatively. The present case demonstrated the efficacy of trastuzumab-containing chemotherapy followed by conversion surgery in a patient with HER2-positive, MSI-H, advanced gastric cancer.

These patients are scheduled to undergo a treatment comprising preoperative chemotherapy with paclitaxel, oxaliplatin and S-1, followed by D2 gastrectomy, and concluding with postoperative treatments that include prophylactic intraperitoneal chemotherapy. The study's primary objective is to evaluate the 3-year peritoneal recurrence rate. Secondary objectives are to assess the 3-year disease-free survival, 3-year overall survival and to monitor the adverse events.Clinical trial registration number: ChiCTR2400083253 (https://www.chictr.org.cn).

P1/2, N=40, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

We report a patient with highly advanced gastric cancer with peritoneal dissemination, which worsened during second-line therapy and was successfully treated with gastrectomy after nivolumab administration as a third-line therapy. MSI-high gastric cancer is a target that should be actively considered for the administration of ICIs, such as nivolumab, and multidisciplinary treatment combined with chemotherapy and gastrectomy, including conversion surgery, can lead to patients' long-term survival.

P1, N=10, Completed, Beijing YouAn Hospital | Unknown status --> Completed | N=18 --> 10

P=N/A, N=30, Recruiting, First affiliated hospital of Soochow university; First affiliated hospital of Soochow university

P3, N=278, Recruiting, Henan Cancer Hospital; Henan Cancer Hospital

P2, N=60, Not yet recruiting, China Medical University Hospital

P2, N=48, Active, not recruiting, National University Hospital, Singapore | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Sep 2024

To our knowledge, this is the first report showing the efficacy of pembrolizumab in a patient with cholangiocarcinoma harboring both HER2-positive and TMB-H.

Advanced gastric adenocarcinoma patients received β-glucan, camrelizumab, oxaliplatin, oral S-1 every 3 weeks...This preliminary study demonstrates that β-glucan plus camrelizumab and SOX chemotherapy offers favorable efficacy and a manageable safety profile in patients with advanced gastric adenocarcinoma, and further studies are needed to verify its efficacy and safety. Chinese Clinical Trials Registry, identifier ChiCTR2100044088.

P3, N=626, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial primary completion date: Dec 2024 --> May 2026

P2, N=116, Not yet recruiting, Xijing Hospital

P3, N=408, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd.

The regimens with >20-fold cost of conventional chemotherapy were used as first-line chemotherapy in two-thirds of patients and more than half even in the elderly population with HER2-negative AGC. This finding is important for future health economic studies on drug cost-efficacy.

P2/3, N=81, Terminated, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=896 --> 81 | Trial completion date: Dec 2027 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Jul 2027 --> Apr 2024; R&d strategy adjustment

Therefore, she was switched to paclitaxel-based therapy. In November 2021, the patient was further switched to nivolumab monotherapy, but she succumbed due to DIC in March 2022. GCs with BMM are prone to DIC, and the SOX regimen, which includes S-1 with efficacy against micrometastases, may constitute a safe and effective treatment modality.

This 3-year follow-up of ATTRACTION-4 confirmed the long-term clinical benefit and manageable safety of nivolumab + chemotherapy in patients with previously untreated advanced gastric cancer.

P2, N=40, Recruiting, The First Affiliated Hospital with Nanjing Medical University

GCS therapy and subsequent CS may contribute to the longer term survival of patients with unresectable upper BTC.

P2, N=30, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

P3, N=626, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial primary completion date: Feb 2027 --> Dec 2024

We report a case of PDAC with liver metastasis and BRCA mutation-positivity who underwent conversion surgery and achieved long-term survival after irinotecan-based chemotherapy followed by maintenance therapy with olaparib.

P2, N=210, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Jul 2027

P2, N=40, Recruiting, Ruijin Hospital

P2, N=198, Not yet recruiting, Sixth Affiliated Hospital, Sun Yat-sen University

P2, N=53, Recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University | Not yet recruiting --> Recruiting

P=N/A, N=37, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

P2, N=122, Recruiting, Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University

P2, N=30, Not yet recruiting, Changzhou Tumor Hospital; Changzhou Tumor Hospital

P2, N=104, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-Sen University Cancer Center

Objective: To evaluate the short-term efficacy and safety of a preoperative combination of programmed cell death protein-1 (PD-1) inhibitor with either oxaliplatin + capecitabine (CapeOx) or oxaliplatin + tegafur gimeracil oteracil potassium (SOX) in the treatment of locally advanced immunotherapy-sensitive gastric cancer (LAGC) or adenocarcinoma of the esophagogastric junction (AEG). All patients recovered with symptomatic treatment. We found that preoperative treatment of patients with LAGC or AEG of one of three types (CPS≥5, dMMR+MSI-H, and EBER positivity) with a PD-1 inhibitor combined with CapeOx or SOX chemotherapy achieved promising effectiveness and safety, with high surgical conversion, R0 resection, and complete response rates.

P2, N=40, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences